Literature DB >> 24104550

Deregulation of cancer-related miRNAs is a common event in both benign and malignant human breast tumors.

Andliena Tahiri1, Suvi-Katri Leivonen, Torben Lüders, Israel Steinfeld, Miriam Ragle Aure, Jürgen Geisler, Rami Mäkelä, Silje Nord, Margit L H Riis, Zohar Yakhini, Kristine Kleivi Sahlberg, Anne-Lise Børresen-Dale, Merja Perälä, Ida R K Bukholm, Vessela N Kristensen.   

Abstract

MicroRNAs (miRNAs) are endogenous non-coding RNAs, which play an essential role in the regulation of gene expression during carcinogenesis. The role of miRNAs in breast cancer has been thoroughly investigated, and although many miRNAs are identified as cancer related, little is known about their involvement in benign tumors. In this study, we investigated miRNA expression profiles in the two most common types of human benign tumors (fibroadenoma/fibroadenomatosis) and in malignant breast tumors and explored their role as oncomirs and tumor suppressor miRNAs. Here, we identified 33 miRNAs with similar deregulated expression in both benign and malignant tumors compared with the expression levels of those in normal tissue, including breast cancer-related miRNAs such as let-7, miR-21 and miR-155. Additionally, messenger RNA (mRNA) expression profiles were obtained for some of the same samples. Using integrated mRNA/miRNA expression analysis, we observed that overexpression of certain miRNAs co-occurred with a significant downregulation of their candidate target mRNAs in both benign and malignant tumors. In support of these findings, in vitro functional screening of the downregulated miRNAs in non-malignant and breast cancer cell lines identified several possible tumor suppressor miRNAs, including miR-193b, miR-193a-3p, miR-126, miR-134, miR-132, miR-486-5p, miR-886-3p, miR-195 and miR-497, showing reduced growth when re-expressed in cancer cells. The finding of deregulated expression of oncomirs and tumor suppressor miRNAs in benign breast tumors is intriguing, indicating that they may play a role in proliferation. A role of cancer-related miRNAs in the early phases of carcinogenesis and malignant transformation can, therefore, not be ruled out.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24104550     DOI: 10.1093/carcin/bgt333

Source DB:  PubMed          Journal:  Carcinogenesis        ISSN: 0143-3334            Impact factor:   4.944


  56 in total

1.  miR-193a-3p functions as a tumor suppressor in lung cancer by down-regulating ERBB4.

Authors:  Hongwei Liang; Minghui Liu; Xin Yan; Yong Zhou; Wengong Wang; Xueliang Wang; Zheng Fu; Nan Wang; Suyang Zhang; Yanbo Wang; Ke Zen; Chen-Yu Zhang; Dongxia Hou; Jing Li; Xi Chen
Journal:  J Biol Chem       Date:  2014-11-12       Impact factor: 5.157

Review 2.  miRNAs as Biomarkers for Predicting the Progression of Ductal Carcinoma in Situ.

Authors:  Bethany N Hannafon; Wei-Qun Ding
Journal:  Am J Pathol       Date:  2017-12-12       Impact factor: 4.307

3.  Combination of circulating miR-19b-3p, miR-122-5p and miR-486-5p expressions correlates with risk and disease severity of knee osteoarthritis.

Authors:  Ruina Kong; Jie Gao; Yanhui Si; Dongbao Zhao
Journal:  Am J Transl Res       Date:  2017-06-15       Impact factor: 4.060

Review 4.  Epithelial-mesenchymal transition transcription factors and miRNAs: "Plastic surgeons" of breast cancer.

Authors:  Caroline Moyret-Lalle; Emmanuelle Ruiz; Alain Puisieux
Journal:  World J Clin Oncol       Date:  2014-08-10

5.  microRNA-195 inhibits cell proliferation in bladder cancer via inhibition of cell division control protein 42 homolog/signal transducer and activator of transcription-3 signaling.

Authors:  Cheng Zhao; Lin Qi; Minfeng Chen; Longfei Liu; Weiqian Yan; Shiyu Tong; Xiongbing Zu
Journal:  Exp Ther Med       Date:  2015-07-09       Impact factor: 2.447

6.  Tumor suppressive microRNA-193b promotes breast cancer progression via targeting DNAJC13 and RAB22A.

Authors:  Zhaoying Yang; Miao He; Keren Wang; Guang Sun; Lu Tang; Zheli Xu
Journal:  Int J Clin Exp Pathol       Date:  2014-10-15

7.  Enhancing identification of cancer types via lowly-expressed microRNAs.

Authors:  Roni Rasnic; Nathan Linial; Michal Linial
Journal:  Nucleic Acids Res       Date:  2017-05-19       Impact factor: 16.971

8.  miR-193a-3p is a Key Tumor Suppressor in Ulcerative Colitis-Associated Colon Cancer and Promotes Carcinogenesis through Upregulation of IL17RD.

Authors:  Joel Pekow; Katherine Meckel; Urszula Dougherty; Yong Huang; Xindi Chen; Anas Almoghrabi; Reba Mustafi; Fatma Ayaloglu-Butun; Zifeng Deng; Haider I Haider; John Hart; David T Rubin; John H Kwon; Marc Bissonnette
Journal:  Clin Cancer Res       Date:  2017-06-09       Impact factor: 12.531

9.  Eribulin upregulates miR-195 expression and downregulates Wnt3a expression in non-basal-like type of triple-negative breast cancer cell MDA-MB-231.

Authors:  Kanji Furuya; Akiko Sasaki; Yuko Tsunoda; Mayumi Tsuji; Yuko Udaka; Hideto Oyamada; Hiromichi Tsuchiya; Katsuji Oguchi
Journal:  Hum Cell       Date:  2015-11-16       Impact factor: 4.174

10.  Crosstalk between microRNA expression and DNA methylation drives the hormone-dependent phenotype of breast cancer.

Authors:  Xavier Tekpli; Vessela N Kristensen; Miriam Ragle Aure; Thomas Fleischer; Sunniva Bjørklund; Jørgen Ankill; Jaime A Castro-Mondragon; Anne-Lise Børresen-Dale; Jörg Tost; Kristine K Sahlberg; Anthony Mathelier
Journal:  Genome Med       Date:  2021-04-29       Impact factor: 11.117

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.